Our anti-SPINK2 in acute myeloid leukemia research

SPINK2 as an adverse prognostic marker in acute myeloid leukemia (AML)

Congratulations to Herbert Augustus Pitts and colleagues at the Chinese University of Hong Kong for their latest publication on AML, one of the most challenging types of leukemia to treat. 

Using next-generation sequencing, Ventana Benchmark Ultra protocol, and our Anti-SPINK2 (HPA026813) Triple A polyclonal, the research shows that SPINK2 (serine protease inhibitor Kazal type 2) expression can be an independent adverse prognostic marker for clinical outcome and therapy resistance in AML. 


The image from Pitts et al, 2023 are representative IHC images of SPINK2 staining (dilution of 1:100) showing strong (A) expression and low/absent (B) expression. in adult AML.

Read the full article: Pitts HA, SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response. Int J Mol Sci. 2023 Jun 2;24(11):9696.


🌎 Our antibodies are used worldwide.

Here are some latest publications.